Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China

You may also be interested in...



Boehringer Threatens Turkish Exit Due To Price Cuts

German drug maker Boehringer Ingelheim GMBH, dismayed by profit declines caused by a series of price cut measures enforced by the Turkish government, has indicated it is considering quitting the Turkish market, but it still hopes to continue research and investment in one of the fastest growing pharmaceutical markets

Boehringer Threatens Turkish Exit Due To Price Cuts

German drug maker Boehringer Ingelheim GMBH, dismayed by profit declines caused by a series of price cut measures enforced by the Turkish government, has indicated it is considering quitting the Turkish market, but it still hopes to continue research and investment in one of the fastest growing pharmaceutical markets

After Running Lilly From China, CEO Says Local Commitment, Innovation Remain Priorities

For almost the entire month of March, Eli Lilly & Co. CEO John Lechleiter ran his company from China, a feat that included hosting Lilly's annual global leadership summit in Shanghai, where 150 high-level Lilly execs gathered to get a firsthand look at the country, visiting hospitals and research centers and meeting with government officials

Related Content

UsernamePublicRestriction

Register

SC076076

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel